nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—osteoarthritis—Prednisone—psoriatic arthritis	0.336	0.5	CpDpCtD
Nabumetone—osteoarthritis—Methylprednisolone—psoriatic arthritis	0.336	0.5	CpDpCtD
Nabumetone—PTGS2—Triamcinolone—psoriatic arthritis	0.0923	0.424	CbGbCtD
Nabumetone—PTGS2—Betamethasone—psoriatic arthritis	0.0792	0.364	CbGbCtD
Nabumetone—PTGS2—Dexamethasone—psoriatic arthritis	0.0461	0.212	CbGbCtD
Nabumetone—MPO—IL23-mediated signaling events—IL23R—psoriatic arthritis	0.00181	0.229	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL23A—psoriatic arthritis	0.00154	0.195	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL17A—psoriatic arthritis	0.000722	0.0913	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL12B—psoriatic arthritis	0.000671	0.0849	CbGpPWpGaD
Nabumetone—PTGS2—Fluocinonide—Methylprednisolone—psoriatic arthritis	0.000566	0.159	CbGdCrCtD
Nabumetone—PTGS2—Fluocinonide—Betamethasone—psoriatic arthritis	0.000557	0.156	CbGdCrCtD
Nabumetone—PTGS2—Fluocinonide—Dexamethasone—psoriatic arthritis	0.000557	0.156	CbGdCrCtD
Nabumetone—PTGS2—Fluocinonide—Triamcinolone—psoriatic arthritis	0.000544	0.153	CbGdCrCtD
Nabumetone—MPO—IL23-mediated signaling events—NOS2—psoriatic arthritis	0.000376	0.0476	CbGpPWpGaD
Nabumetone—PTGS2—Fluticasone Propionate—Methylprednisolone—psoriatic arthritis	0.000341	0.0958	CbGdCrCtD
Nabumetone—PTGS2—Fluticasone Propionate—Dexamethasone—psoriatic arthritis	0.000336	0.0943	CbGdCrCtD
Nabumetone—PTGS2—Fluticasone Propionate—Betamethasone—psoriatic arthritis	0.000336	0.0943	CbGdCrCtD
Nabumetone—PTGS2—Fluticasone Propionate—Triamcinolone—psoriatic arthritis	0.000328	0.0921	CbGdCrCtD
Nabumetone—MPO—Vitamin B12 Metabolism—CRP—psoriatic arthritis	0.000319	0.0404	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000288	0.0364	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—CRP—psoriatic arthritis	0.00026	0.0328	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000228	0.0289	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000206	0.0261	CbGpPWpGaD
Nabumetone—Myocardial infarction—Prednisone—psoriatic arthritis	0.00019	0.00193	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.000189	0.00192	CcSEcCtD
Nabumetone—Malaise—Prednisolone—psoriatic arthritis	0.000188	0.00191	CcSEcCtD
Nabumetone—Vertigo—Prednisolone—psoriatic arthritis	0.000187	0.0019	CcSEcCtD
Nabumetone—Syncope—Prednisolone—psoriatic arthritis	0.000187	0.0019	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—TNF—psoriatic arthritis	0.000187	0.0236	CbGpPWpGaD
Nabumetone—Loss of consciousness—Prednisolone—psoriatic arthritis	0.000183	0.00186	CcSEcCtD
Nabumetone—Asthma—Methotrexate—psoriatic arthritis	0.000182	0.00185	CcSEcCtD
Nabumetone—Hypertension—Prednisolone—psoriatic arthritis	0.00018	0.00183	CcSEcCtD
Nabumetone—Arrhythmia—Dexamethasone—psoriatic arthritis	0.000178	0.00181	CcSEcCtD
Nabumetone—Arrhythmia—Betamethasone—psoriatic arthritis	0.000178	0.00181	CcSEcCtD
Nabumetone—Pancreatitis—Methotrexate—psoriatic arthritis	0.000178	0.00181	CcSEcCtD
Nabumetone—Ill-defined disorder—Triamcinolone—psoriatic arthritis	0.000178	0.00181	CcSEcCtD
Nabumetone—Ill-defined disorder—Methylprednisolone—psoriatic arthritis	0.000177	0.0018	CcSEcCtD
Nabumetone—Alopecia—Betamethasone—psoriatic arthritis	0.000176	0.00179	CcSEcCtD
Nabumetone—Alopecia—Dexamethasone—psoriatic arthritis	0.000176	0.00179	CcSEcCtD
Nabumetone—Discomfort—Prednisolone—psoriatic arthritis	0.000175	0.00178	CcSEcCtD
Nabumetone—Angioedema—Triamcinolone—psoriatic arthritis	0.000175	0.00178	CcSEcCtD
Nabumetone—Haemoglobin—Prednisone—psoriatic arthritis	0.000175	0.00178	CcSEcCtD
Nabumetone—Angioedema—Methylprednisolone—psoriatic arthritis	0.000175	0.00178	CcSEcCtD
Nabumetone—Haemorrhage—Prednisone—psoriatic arthritis	0.000174	0.00177	CcSEcCtD
Nabumetone—Malaise—Triamcinolone—psoriatic arthritis	0.000173	0.00176	CcSEcCtD
Nabumetone—Malaise—Methylprednisolone—psoriatic arthritis	0.000172	0.00175	CcSEcCtD
Nabumetone—Vertigo—Triamcinolone—psoriatic arthritis	0.000172	0.00175	CcSEcCtD
Nabumetone—Syncope—Triamcinolone—psoriatic arthritis	0.000172	0.00175	CcSEcCtD
Nabumetone—Vertigo—Methylprednisolone—psoriatic arthritis	0.000172	0.00175	CcSEcCtD
Nabumetone—Syncope—Methylprednisolone—psoriatic arthritis	0.000171	0.00174	CcSEcCtD
Nabumetone—Oedema—Prednisolone—psoriatic arthritis	0.00017	0.00173	CcSEcCtD
Nabumetone—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00017	0.00173	CcSEcCtD
Nabumetone—Dysuria—Methotrexate—psoriatic arthritis	0.00017	0.00173	CcSEcCtD
Nabumetone—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.000168	0.00171	CcSEcCtD
Nabumetone—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000168	0.00171	CcSEcCtD
Nabumetone—Shock—Prednisolone—psoriatic arthritis	0.000167	0.0017	CcSEcCtD
Nabumetone—Erectile dysfunction—Methotrexate—psoriatic arthritis	0.000167	0.0017	CcSEcCtD
Nabumetone—Cough—Triamcinolone—psoriatic arthritis	0.000167	0.0017	CcSEcCtD
Nabumetone—Photosensitivity reaction—Methotrexate—psoriatic arthritis	0.000166	0.00168	CcSEcCtD
Nabumetone—Hypertension—Triamcinolone—psoriatic arthritis	0.000165	0.00168	CcSEcCtD
Nabumetone—Hypertension—Methylprednisolone—psoriatic arthritis	0.000165	0.00168	CcSEcCtD
Nabumetone—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.000164	0.00167	CcSEcCtD
Nabumetone—Pneumonia—Methotrexate—psoriatic arthritis	0.000163	0.00166	CcSEcCtD
Nabumetone—Anxiety—Methylprednisolone—psoriatic arthritis	0.000162	0.00165	CcSEcCtD
Nabumetone—Depression—Methotrexate—psoriatic arthritis	0.000161	0.00164	CcSEcCtD
Nabumetone—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.000161	0.00164	CcSEcCtD
Nabumetone—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.000161	0.00164	CcSEcCtD
Nabumetone—Discomfort—Triamcinolone—psoriatic arthritis	0.000161	0.00164	CcSEcCtD
Nabumetone—Discomfort—Methylprednisolone—psoriatic arthritis	0.000161	0.00163	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.00016	0.00163	CcSEcCtD
Nabumetone—Dry mouth—Triamcinolone—psoriatic arthritis	0.00016	0.00162	CcSEcCtD
Nabumetone—Renal failure—Methotrexate—psoriatic arthritis	0.000159	0.00162	CcSEcCtD
Nabumetone—Angioedema—Betamethasone—psoriatic arthritis	0.000159	0.00161	CcSEcCtD
Nabumetone—Angioedema—Dexamethasone—psoriatic arthritis	0.000159	0.00161	CcSEcCtD
Nabumetone—Stomatitis—Methotrexate—psoriatic arthritis	0.000158	0.0016	CcSEcCtD
Nabumetone—Confusional state—Methylprednisolone—psoriatic arthritis	0.000157	0.0016	CcSEcCtD
Nabumetone—Malaise—Betamethasone—psoriatic arthritis	0.000157	0.00159	CcSEcCtD
Nabumetone—Malaise—Dexamethasone—psoriatic arthritis	0.000157	0.00159	CcSEcCtD
Nabumetone—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000156	0.00159	CcSEcCtD
Nabumetone—Oedema—Triamcinolone—psoriatic arthritis	0.000156	0.00159	CcSEcCtD
Nabumetone—Vertigo—Betamethasone—psoriatic arthritis	0.000156	0.00159	CcSEcCtD
Nabumetone—Vertigo—Dexamethasone—psoriatic arthritis	0.000156	0.00159	CcSEcCtD
Nabumetone—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000156	0.00159	CcSEcCtD
Nabumetone—Syncope—Dexamethasone—psoriatic arthritis	0.000156	0.00158	CcSEcCtD
Nabumetone—Syncope—Betamethasone—psoriatic arthritis	0.000156	0.00158	CcSEcCtD
Nabumetone—Arrhythmia—Prednisone—psoriatic arthritis	0.000155	0.00158	CcSEcCtD
Nabumetone—Haematuria—Methotrexate—psoriatic arthritis	0.000154	0.00157	CcSEcCtD
Nabumetone—Shock—Triamcinolone—psoriatic arthritis	0.000154	0.00156	CcSEcCtD
Nabumetone—Insomnia—Prednisolone—psoriatic arthritis	0.000154	0.00156	CcSEcCtD
Nabumetone—Alopecia—Prednisone—psoriatic arthritis	0.000154	0.00156	CcSEcCtD
Nabumetone—Shock—Methylprednisolone—psoriatic arthritis	0.000153	0.00156	CcSEcCtD
Nabumetone—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000153	0.00155	CcSEcCtD
Nabumetone—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000153	0.00155	CcSEcCtD
Nabumetone—Paraesthesia—Prednisolone—psoriatic arthritis	0.000153	0.00155	CcSEcCtD
Nabumetone—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000151	0.00154	CcSEcCtD
Nabumetone—Agranulocytosis—Methotrexate—psoriatic arthritis	0.000151	0.00154	CcSEcCtD
Nabumetone—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000151	0.00153	CcSEcCtD
Nabumetone—Hypertension—Dexamethasone—psoriatic arthritis	0.00015	0.00153	CcSEcCtD
Nabumetone—Hypertension—Betamethasone—psoriatic arthritis	0.00015	0.00153	CcSEcCtD
Nabumetone—Anxiety—Betamethasone—psoriatic arthritis	0.000147	0.0015	CcSEcCtD
Nabumetone—Anxiety—Dexamethasone—psoriatic arthritis	0.000147	0.0015	CcSEcCtD
Nabumetone—Discomfort—Betamethasone—psoriatic arthritis	0.000146	0.00149	CcSEcCtD
Nabumetone—Discomfort—Dexamethasone—psoriatic arthritis	0.000146	0.00149	CcSEcCtD
Nabumetone—Haemoglobin—Methotrexate—psoriatic arthritis	0.000146	0.00148	CcSEcCtD
Nabumetone—Haemorrhage—Methotrexate—psoriatic arthritis	0.000145	0.00148	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—TNF—psoriatic arthritis	0.000144	0.0183	CbGpPWpGaD
Nabumetone—Oedema—Betamethasone—psoriatic arthritis	0.000142	0.00144	CcSEcCtD
Nabumetone—Oedema—Dexamethasone—psoriatic arthritis	0.000142	0.00144	CcSEcCtD
Nabumetone—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000142	0.00144	CcSEcCtD
Nabumetone—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000142	0.00144	CcSEcCtD
Nabumetone—Insomnia—Triamcinolone—psoriatic arthritis	0.000141	0.00144	CcSEcCtD
Nabumetone—Insomnia—Methylprednisolone—psoriatic arthritis	0.000141	0.00143	CcSEcCtD
Nabumetone—Ill-defined disorder—Prednisone—psoriatic arthritis	0.00014	0.00143	CcSEcCtD
Nabumetone—Paraesthesia—Triamcinolone—psoriatic arthritis	0.00014	0.00143	CcSEcCtD
Nabumetone—Feeling abnormal—Prednisolone—psoriatic arthritis	0.00014	0.00142	CcSEcCtD
Nabumetone—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.00014	0.00142	CcSEcCtD
Nabumetone—Visual impairment—Methotrexate—psoriatic arthritis	0.00014	0.00142	CcSEcCtD
Nabumetone—Anaemia—Prednisone—psoriatic arthritis	0.00014	0.00142	CcSEcCtD
Nabumetone—Shock—Dexamethasone—psoriatic arthritis	0.00014	0.00142	CcSEcCtD
Nabumetone—Shock—Betamethasone—psoriatic arthritis	0.00014	0.00142	CcSEcCtD
Nabumetone—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000139	0.00142	CcSEcCtD
Nabumetone—Agitation—Prednisone—psoriatic arthritis	0.000139	0.00141	CcSEcCtD
Nabumetone—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000139	0.00141	CcSEcCtD
Nabumetone—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000139	0.00141	CcSEcCtD
Nabumetone—Angioedema—Prednisone—psoriatic arthritis	0.000138	0.00141	CcSEcCtD
Nabumetone—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000138	0.0014	CcSEcCtD
Nabumetone—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000137	0.0014	CcSEcCtD
Nabumetone—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000137	0.0014	CcSEcCtD
Nabumetone—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000137	0.00139	CcSEcCtD
Nabumetone—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000137	0.00139	CcSEcCtD
Nabumetone—Malaise—Prednisone—psoriatic arthritis	0.000137	0.00139	CcSEcCtD
Nabumetone—Vertigo—Prednisone—psoriatic arthritis	0.000136	0.00138	CcSEcCtD
Nabumetone—Syncope—Prednisone—psoriatic arthritis	0.000136	0.00138	CcSEcCtD
Nabumetone—Tinnitus—Methotrexate—psoriatic arthritis	0.000135	0.00138	CcSEcCtD
Nabumetone—Anorexia—Dexamethasone—psoriatic arthritis	0.000135	0.00137	CcSEcCtD
Nabumetone—Anorexia—Betamethasone—psoriatic arthritis	0.000135	0.00137	CcSEcCtD
Nabumetone—Urticaria—Prednisolone—psoriatic arthritis	0.000135	0.00137	CcSEcCtD
Nabumetone—Fatigue—Triamcinolone—psoriatic arthritis	0.000135	0.00137	CcSEcCtD
Nabumetone—Fatigue—Methylprednisolone—psoriatic arthritis	0.000134	0.00137	CcSEcCtD
Nabumetone—Loss of consciousness—Prednisone—psoriatic arthritis	0.000133	0.00135	CcSEcCtD
Nabumetone—Hypertension—Prednisone—psoriatic arthritis	0.000131	0.00133	CcSEcCtD
Nabumetone—Chills—Methotrexate—psoriatic arthritis	0.00013	0.00133	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.00013	0.0165	CbGpPWpGaD
Nabumetone—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000129	0.00131	CcSEcCtD
Nabumetone—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000129	0.00131	CcSEcCtD
Nabumetone—Anxiety—Prednisone—psoriatic arthritis	0.000128	0.00131	CcSEcCtD
Nabumetone—Alopecia—Methotrexate—psoriatic arthritis	0.000128	0.00131	CcSEcCtD
Nabumetone—Insomnia—Dexamethasone—psoriatic arthritis	0.000128	0.0013	CcSEcCtD
Nabumetone—Insomnia—Betamethasone—psoriatic arthritis	0.000128	0.0013	CcSEcCtD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.000128	0.0162	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000128	0.0013	CcSEcCtD
Nabumetone—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000127	0.00129	CcSEcCtD
Nabumetone—Paraesthesia—Betamethasone—psoriatic arthritis	0.000127	0.00129	CcSEcCtD
Nabumetone—Discomfort—Prednisone—psoriatic arthritis	0.000127	0.00129	CcSEcCtD
Nabumetone—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000125	0.00127	CcSEcCtD
Nabumetone—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000125	0.00127	CcSEcCtD
Nabumetone—Dyspepsia—Betamethasone—psoriatic arthritis	0.000125	0.00127	CcSEcCtD
Nabumetone—Urticaria—Triamcinolone—psoriatic arthritis	0.000124	0.00126	CcSEcCtD
Nabumetone—Urticaria—Methylprednisolone—psoriatic arthritis	0.000124	0.00126	CcSEcCtD
Nabumetone—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000124	0.00126	CcSEcCtD
Nabumetone—Oedema—Prednisone—psoriatic arthritis	0.000124	0.00126	CcSEcCtD
Nabumetone—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000124	0.00126	CcSEcCtD
Nabumetone—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000123	0.00125	CcSEcCtD
Nabumetone—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000123	0.00125	CcSEcCtD
Nabumetone—Decreased appetite—Betamethasone—psoriatic arthritis	0.000123	0.00125	CcSEcCtD
Nabumetone—Fatigue—Dexamethasone—psoriatic arthritis	0.000122	0.00124	CcSEcCtD
Nabumetone—Fatigue—Betamethasone—psoriatic arthritis	0.000122	0.00124	CcSEcCtD
Nabumetone—Shock—Prednisone—psoriatic arthritis	0.000122	0.00124	CcSEcCtD
Nabumetone—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000119	0.00121	CcSEcCtD
Nabumetone—Anorexia—Prednisone—psoriatic arthritis	0.000118	0.0012	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—TNF—psoriatic arthritis	0.000118	0.0149	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.000117	0.00119	CcSEcCtD
Nabumetone—Anaemia—Methotrexate—psoriatic arthritis	0.000117	0.00119	CcSEcCtD
Nabumetone—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000117	0.00119	CcSEcCtD
Nabumetone—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000117	0.00119	CcSEcCtD
Nabumetone—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000116	0.00118	CcSEcCtD
Nabumetone—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000116	0.00118	CcSEcCtD
Nabumetone—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000115	0.00117	CcSEcCtD
Nabumetone—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000115	0.00117	CcSEcCtD
Nabumetone—Malaise—Methotrexate—psoriatic arthritis	0.000114	0.00116	CcSEcCtD
Nabumetone—Vertigo—Methotrexate—psoriatic arthritis	0.000114	0.00116	CcSEcCtD
Nabumetone—Leukopenia—Methotrexate—psoriatic arthritis	0.000113	0.00115	CcSEcCtD
Nabumetone—Urticaria—Dexamethasone—psoriatic arthritis	0.000113	0.00115	CcSEcCtD
Nabumetone—Urticaria—Betamethasone—psoriatic arthritis	0.000113	0.00115	CcSEcCtD
Nabumetone—Dizziness—Prednisolone—psoriatic arthritis	0.000112	0.00114	CcSEcCtD
Nabumetone—Asthenia—Triamcinolone—psoriatic arthritis	0.000112	0.00114	CcSEcCtD
Nabumetone—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000112	0.00114	CcSEcCtD
Nabumetone—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000112	0.00114	CcSEcCtD
Nabumetone—Abdominal pain—Betamethasone—psoriatic arthritis	0.000112	0.00114	CcSEcCtD
Nabumetone—Body temperature increased—Betamethasone—psoriatic arthritis	0.000112	0.00114	CcSEcCtD
Nabumetone—Asthenia—Methylprednisolone—psoriatic arthritis	0.000112	0.00114	CcSEcCtD
Nabumetone—Insomnia—Prednisone—psoriatic arthritis	0.000112	0.00114	CcSEcCtD
Nabumetone—Paraesthesia—Prednisone—psoriatic arthritis	0.000111	0.00113	CcSEcCtD
Nabumetone—Pruritus—Triamcinolone—psoriatic arthritis	0.000111	0.00112	CcSEcCtD
Nabumetone—Cough—Methotrexate—psoriatic arthritis	0.00011	0.00112	CcSEcCtD
Nabumetone—Pruritus—Methylprednisolone—psoriatic arthritis	0.00011	0.00112	CcSEcCtD
Nabumetone—Dyspepsia—Prednisone—psoriatic arthritis	0.000109	0.00111	CcSEcCtD
Nabumetone—Decreased appetite—Prednisone—psoriatic arthritis	0.000107	0.00109	CcSEcCtD
Nabumetone—Rash—Prednisolone—psoriatic arthritis	0.000107	0.00109	CcSEcCtD
Nabumetone—Dermatitis—Prednisolone—psoriatic arthritis	0.000107	0.00109	CcSEcCtD
Nabumetone—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000107	0.00108	CcSEcCtD
Nabumetone—Fatigue—Prednisone—psoriatic arthritis	0.000107	0.00108	CcSEcCtD
Nabumetone—Headache—Prednisolone—psoriatic arthritis	0.000107	0.00108	CcSEcCtD
Nabumetone—Discomfort—Methotrexate—psoriatic arthritis	0.000106	0.00108	CcSEcCtD
Nabumetone—Constipation—Prednisone—psoriatic arthritis	0.000106	0.00107	CcSEcCtD
Nabumetone—Confusional state—Methotrexate—psoriatic arthritis	0.000104	0.00106	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000104	0.0131	CbGpPWpGaD
Nabumetone—Dizziness—Triamcinolone—psoriatic arthritis	0.000103	0.00105	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000103	0.0131	CbGpPWpGaD
Nabumetone—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000103	0.00105	CcSEcCtD
Nabumetone—Dizziness—Methylprednisolone—psoriatic arthritis	0.000103	0.00105	CcSEcCtD
Nabumetone—Feeling abnormal—Prednisone—psoriatic arthritis	0.000102	0.00103	CcSEcCtD
Nabumetone—Asthenia—Dexamethasone—psoriatic arthritis	0.000102	0.00103	CcSEcCtD
Nabumetone—Asthenia—Betamethasone—psoriatic arthritis	0.000102	0.00103	CcSEcCtD
Nabumetone—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000101	0.00103	CcSEcCtD
Nabumetone—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000101	0.00103	CcSEcCtD
Nabumetone—Nausea—Prednisolone—psoriatic arthritis	0.000101	0.00103	CcSEcCtD
Nabumetone—Pruritus—Betamethasone—psoriatic arthritis	0.0001	0.00102	CcSEcCtD
Nabumetone—Pruritus—Dexamethasone—psoriatic arthritis	0.0001	0.00102	CcSEcCtD
Nabumetone—Hyperhidrosis—Methotrexate—psoriatic arthritis	9.98e-05	0.00101	CcSEcCtD
Nabumetone—Vomiting—Triamcinolone—psoriatic arthritis	9.94e-05	0.00101	CcSEcCtD
Nabumetone—Vomiting—Methylprednisolone—psoriatic arthritis	9.92e-05	0.00101	CcSEcCtD
Nabumetone—Rash—Triamcinolone—psoriatic arthritis	9.86e-05	0.001	CcSEcCtD
Nabumetone—Dermatitis—Triamcinolone—psoriatic arthritis	9.85e-05	0.001	CcSEcCtD
Nabumetone—Anorexia—Methotrexate—psoriatic arthritis	9.84e-05	0.001	CcSEcCtD
Nabumetone—Rash—Methylprednisolone—psoriatic arthritis	9.84e-05	0.001	CcSEcCtD
Nabumetone—Dermatitis—Methylprednisolone—psoriatic arthritis	9.83e-05	0.000999	CcSEcCtD
Nabumetone—Urticaria—Prednisone—psoriatic arthritis	9.81e-05	0.000998	CcSEcCtD
Nabumetone—Headache—Triamcinolone—psoriatic arthritis	9.79e-05	0.000996	CcSEcCtD
Nabumetone—Headache—Methylprednisolone—psoriatic arthritis	9.77e-05	0.000993	CcSEcCtD
Nabumetone—Abdominal pain—Prednisone—psoriatic arthritis	9.77e-05	0.000993	CcSEcCtD
Nabumetone—Body temperature increased—Prednisone—psoriatic arthritis	9.77e-05	0.000993	CcSEcCtD
Nabumetone—Diarrhoea—Betamethasone—psoriatic arthritis	9.71e-05	0.000987	CcSEcCtD
Nabumetone—Diarrhoea—Dexamethasone—psoriatic arthritis	9.71e-05	0.000987	CcSEcCtD
Nabumetone—Dizziness—Betamethasone—psoriatic arthritis	9.38e-05	0.000954	CcSEcCtD
Nabumetone—Dizziness—Dexamethasone—psoriatic arthritis	9.38e-05	0.000954	CcSEcCtD
Nabumetone—Insomnia—Methotrexate—psoriatic arthritis	9.34e-05	0.000949	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—TNF—psoriatic arthritis	9.34e-05	0.0118	CbGpPWpGaD
Nabumetone—Nausea—Triamcinolone—psoriatic arthritis	9.29e-05	0.000944	CcSEcCtD
Nabumetone—Paraesthesia—Methotrexate—psoriatic arthritis	9.27e-05	0.000942	CcSEcCtD
Nabumetone—Nausea—Methylprednisolone—psoriatic arthritis	9.27e-05	0.000942	CcSEcCtD
Nabumetone—Dyspnoea—Methotrexate—psoriatic arthritis	9.2e-05	0.000936	CcSEcCtD
Nabumetone—Somnolence—Methotrexate—psoriatic arthritis	9.18e-05	0.000933	CcSEcCtD
Nabumetone—Hypersensitivity—Prednisone—psoriatic arthritis	9.1e-05	0.000925	CcSEcCtD
Nabumetone—Dyspepsia—Methotrexate—psoriatic arthritis	9.09e-05	0.000924	CcSEcCtD
Nabumetone—Vomiting—Dexamethasone—psoriatic arthritis	9.02e-05	0.000917	CcSEcCtD
Nabumetone—Vomiting—Betamethasone—psoriatic arthritis	9.02e-05	0.000917	CcSEcCtD
Nabumetone—Decreased appetite—Methotrexate—psoriatic arthritis	8.98e-05	0.000912	CcSEcCtD
Nabumetone—Rash—Dexamethasone—psoriatic arthritis	8.94e-05	0.000909	CcSEcCtD
Nabumetone—Rash—Betamethasone—psoriatic arthritis	8.94e-05	0.000909	CcSEcCtD
Nabumetone—Dermatitis—Betamethasone—psoriatic arthritis	8.94e-05	0.000908	CcSEcCtD
Nabumetone—Dermatitis—Dexamethasone—psoriatic arthritis	8.94e-05	0.000908	CcSEcCtD
Nabumetone—Fatigue—Methotrexate—psoriatic arthritis	8.9e-05	0.000905	CcSEcCtD
Nabumetone—Headache—Betamethasone—psoriatic arthritis	8.89e-05	0.000903	CcSEcCtD
Nabumetone—Headache—Dexamethasone—psoriatic arthritis	8.89e-05	0.000903	CcSEcCtD
Nabumetone—Asthenia—Prednisone—psoriatic arthritis	8.86e-05	0.000901	CcSEcCtD
Nabumetone—Pruritus—Prednisone—psoriatic arthritis	8.74e-05	0.000888	CcSEcCtD
Nabumetone—Feeling abnormal—Methotrexate—psoriatic arthritis	8.51e-05	0.000865	CcSEcCtD
Nabumetone—Diarrhoea—Prednisone—psoriatic arthritis	8.45e-05	0.000859	CcSEcCtD
Nabumetone—Gastrointestinal pain—Methotrexate—psoriatic arthritis	8.44e-05	0.000858	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—CRP—psoriatic arthritis	8.44e-05	0.0107	CbGpPWpGaD
Nabumetone—Nausea—Betamethasone—psoriatic arthritis	8.43e-05	0.000857	CcSEcCtD
Nabumetone—Nausea—Dexamethasone—psoriatic arthritis	8.43e-05	0.000857	CcSEcCtD
Nabumetone—Urticaria—Methotrexate—psoriatic arthritis	8.2e-05	0.000834	CcSEcCtD
Nabumetone—Dizziness—Prednisone—psoriatic arthritis	8.17e-05	0.00083	CcSEcCtD
Nabumetone—Abdominal pain—Methotrexate—psoriatic arthritis	8.16e-05	0.00083	CcSEcCtD
Nabumetone—Body temperature increased—Methotrexate—psoriatic arthritis	8.16e-05	0.00083	CcSEcCtD
Nabumetone—Vomiting—Prednisone—psoriatic arthritis	7.85e-05	0.000798	CcSEcCtD
Nabumetone—Rash—Prednisone—psoriatic arthritis	7.79e-05	0.000792	CcSEcCtD
Nabumetone—Dermatitis—Prednisone—psoriatic arthritis	7.78e-05	0.000791	CcSEcCtD
Nabumetone—Headache—Prednisone—psoriatic arthritis	7.74e-05	0.000787	CcSEcCtD
Nabumetone—Hypersensitivity—Methotrexate—psoriatic arthritis	7.61e-05	0.000773	CcSEcCtD
Nabumetone—Asthenia—Methotrexate—psoriatic arthritis	7.41e-05	0.000753	CcSEcCtD
Nabumetone—Nausea—Prednisone—psoriatic arthritis	7.34e-05	0.000746	CcSEcCtD
Nabumetone—Pruritus—Methotrexate—psoriatic arthritis	7.3e-05	0.000742	CcSEcCtD
Nabumetone—Diarrhoea—Methotrexate—psoriatic arthritis	7.06e-05	0.000718	CcSEcCtD
Nabumetone—Dizziness—Methotrexate—psoriatic arthritis	6.83e-05	0.000694	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—CRP—psoriatic arthritis	6.7e-05	0.00848	CbGpPWpGaD
Nabumetone—Vomiting—Methotrexate—psoriatic arthritis	6.56e-05	0.000667	CcSEcCtD
Nabumetone—Rash—Methotrexate—psoriatic arthritis	6.51e-05	0.000662	CcSEcCtD
Nabumetone—Dermatitis—Methotrexate—psoriatic arthritis	6.5e-05	0.000661	CcSEcCtD
Nabumetone—Headache—Methotrexate—psoriatic arthritis	6.47e-05	0.000657	CcSEcCtD
Nabumetone—Nausea—Methotrexate—psoriatic arthritis	6.13e-05	0.000623	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	5.1e-05	0.00645	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—NOS2—psoriatic arthritis	4.83e-05	0.00611	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	4.77e-05	0.00603	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—TNF—psoriatic arthritis	3.82e-05	0.00483	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—TNF—psoriatic arthritis	3.03e-05	0.00384	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	2.88e-05	0.00365	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	2.88e-05	0.00365	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TNF—psoriatic arthritis	2.4e-05	0.00303	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	1.63e-05	0.00206	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NOS2—psoriatic arthritis	7.3e-06	0.000923	CbGpPWpGaD
